FDA Advisory Committee Meeting Planned To Review Atrial Fibrillation Drugs

Safety and efficacy of Cardiome/Astellas’ vernakalant and Solvay’s tedisamil will be debated during the Dec. 11-12 meeting, according to Cardiome.

More from Archive

More from Pink Sheet